【摘要】 目的 :观察伊曲康唑口服液治疗口腔念珠菌病的临床疗效及安全性。方法 :采取单盲、区组随机对照研究。完成病人 78例 ,其中口服液组 4 0例[男性 4例 ,女性 36例 ,年龄为 (5 5±s 11)a],服用伊曲康唑口服液 ;胶囊组 38例 [男性 7例 ,女性 31例 ,年龄 (5 3± 9)a],服用伊曲康唑胶囊。口服液组和胶囊组均按 10 0mg ,po ,bid。疗程 14d。结果 :服药 2wk后口服液组总有效率为 84 % ,真菌消除率为 97% ,不良反应发生率为 2 0 % ,胶囊组总有效率 89% ,真菌消除率为 72 % ,不良反应发生率为8% ,2组总有效率、不良反应发生率差异均无显著意义 (P >0 .0 5 )。但治疗 2wk时 ,口服液组的真菌消除率明显高于胶囊组 (P <0 .0 5 )。结论 :伊曲康唑口服液治疗口腔念珠菌病有明显疗效、不良反应少。更多还原

【Abstract】 AIM: To evaluate the efficacy and safety of itraconazole oral solution vs capsule in the treatment of oral candidiasis. METHODS: A total of 78 patients with oral candidiasis confirmed by clinical and mycological methods were enrolled in this study. The patients were randomly divided into treatment group (treated with itraconazole oral solution, 40 patients) and control group (treated with itraconazole capsule, 38 patients). Oral administration of itraconazole 100 mg twice a day up to 14 d were used in those patients. RESULTS: The total effective rate in treatment group vs control group for 2 wk treatment was 84 % and 89 %, respectively. There were no significant difference of the total effective rate between two groups (P>0.05), but the candida clearance rate of the treatment group after 2 wk treatment is higher than that of the control group(P< 0.05). The adverse reactions rate of two groups was 20 % in treatment group when compared to 8 % in the control group. No significant adverse reactions were noted. CONCLUSION: Itraconazole oral solution 100 mg twice daily can be effective for treating the patients with oral candidiasis with its characteristic of high efficiency as well as convenient and lower adverse reactions and is one of relatively ideal antifungal agent for oral candidiasis.更多还原